Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shaking Off US Rebuff, Gilead And Galapagos Get Filgotinib Green Lights In EU And Japan

First Ever Approvals For Belgian Biotech

Executive Summary

Galapagos and Gilead's JAK inhibitor has been approved for rheumatoid arthritis in the second and third biggest pharma markets, softening the blow somewhat of rejection from the US FDA in the biggest market last month.

You may also be interested in...



MANTA Brings Glimmer Of Good News To Galapagos

After a difficult spell for the Belgian biotech, positive interim data from two key studies looking at testicular toxicity concerns over filgotinib suggest a pathway for potential future US approval of the Gilead-partnered JAK inhibitor for IBD.

Filgotinib On Uncertain Path As Gilead Regains Speed From Pandemic Hit

Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.

BMS Sees Zeposia As Safer Oral Option In Ulcerative Colitis

Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143034

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel